Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have shown remarkable therapeutic outcomes among cancer patients. Durvalumab plus tremelimumab (DT) is under investigation as a new ICI combination therapy, and its efficacy has been reported in various types of cancer. However, the safety profile of DT remains unclear, especially considering rare adverse events (AEs).

Objective

We aimed to assess the frequency of AEs associated with DT.

Design

This study type is a systematic review and meta-analysis.

Data sources and methods

Four databases were searched for articles. Randomized trials, single-arm trials, and prospective and retrospective observational studies were included. The type of cancer, previous treatment, and performance status were not questioned. Major A

SUBMITTER: Matsumoto H 

PROVIDER: S-EPMC10501063 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature